Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Anton Yelchin Foundation Donates $1M to USC’s Adult Cystic Fibrosis Clinic at Keck Hospital I’ve Allowed My Disease to Abuse My Energy #NACFC2018 – RPL554 Shows Promising Results in CF Studies Anton Yelchin Foundation Donates $1M to USC’s Adult Cystic Fibrosis Clinic at Keck Hospital Nov 07, 2018 07:00 am | Iqra Mumal The Anton Yelchin Foundation has donated $1 million to the University of Southern California (USC) Center for Cystic Fibrosis – Adult Care at Keck Hospital to thank the center for its efforts in managing the healthcare of the late American actor. Yelchin, who had cystic fibrosis (CF), was cared for at the USC Center for Cystic Fibrosis – […] The post Anton Yelchin Foundation Donates $1M to USC’s Adult Cystic Fibrosis Clinic at Keck Hospital appeared first on Cystic Fibrosis News Today. Read More I’ve Allowed My Disease to Abuse My Energy Nov 06, 2018 09:00 am | Brad Dell Well, it finally happened: Twenty-two months after my double-lung transplant, I finally got sick for the first time. I gotta say, with a suppressed immune system, illness isn’t so lovely. I saw the docs last Tuesday, and they ran a panel of tests. No results yet, but I’m fatigued and coughing up globs of green […] The post I’ve Allowed My Disease to Abuse My Energy appeared first on Cystic Fibrosis News Today. Read More #NACFC2018 – RPL554 Shows Promising Results in CF Studies Nov 06, 2018 07:00 am | Vijaya Iyer Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented at the 2018 North American Cystic Fibrosis Conference (NACFC) in Denver, Colorado (Oct. 18-20). RPL554, developed by Verona Pharma, is an inhaled potential therapy for CF and chronic obstructive pulmonary disease (COPD). It is the first drug of its kind designed […] The post #NACFC2018 – RPL554 Shows Promising Results in CF Studies appeared first on Cystic Fibrosis News Today. Read More   Recent News Exciting Revelations from the NACFC 2018 Poster Sessions, Part 2 AbbVie Takes Sole Control of Potential CF Therapies Developed with Galapagos Symkevi Approved in EU for CF Patients with Two F508del Mutations, or One Plus a Minimal Function Mutation Exciting Revelations from the NACFC 2018 Poster Sessions, Part 1 Vertex Announces Plans for Symdeko, Hopes for Triple Combos Now in Pivotal Trials